02 November 2017
: Case report
Recurrent Thrombosis: A Case of Hereditary Thromboembolism
Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Congenital defects / diseases
Maria Concetta Giofrè1E*, Francesca Napoli1B, Daniela La Rosa1C, Alessia Caruso1G, Natascia Laganà1D, Lucia Orlando Settembrini2C, Antonino Saitta1F, Antonio Giovanni Versace1ADOI: 10.12659/AJCR.906035
Am J Case Rep 2017; 18:1157-1159
Abstract
BACKGROUND: Thrombophilia is a predisposition to thrombosis. Genetic causes include antithrombin III, protein C, protein S, factor V Leiden, prothrombin 20210A allele, and MTHFR mutations. Other genetic factors causing thrombosis and pulmonary embolism have been identified in recent studies, including 4G/4G polymorphism of the PAI-1 gene.
CASE REPORT: A patient with a personal and family history of recurrent thrombosis and pulmonary embolism was admitted to our Internal Medicine Department. After the most common acquired risk factors for thromboembolism were ruled out, the patient and her family members underwent genetic diagnostic testing. These tests showed homozygous 4G/4G polymorphism of the PAI-1 gene in 14 subjects, homozygous 4G/4G polymorphism of the PAI-1 gene and C677T/A1298C polymorphism of the MTHFR gene in 4 subjects, and heterozygous 4G/4G polymorphism of the PAI-1 gene and C677T/A1298C polymorphism of the MTHFR gene in 3 subjects. Afterwards, we initiated the administration of Rivaroxaban, with beneficial results.
CONCLUSIONS: No thrombotic recurrence has been observed in the patient since 2014. This case report shows the efficacy and superiority of Rivaroxaban over traditional anticoagulants in the treatment of hereditary thrombophilia. Further studies are clearly needed before Rivaroxaban can be recommended as a standard treatment in patients with inherited thrombophilia.
Keywords: Anticoagulants, Factor X, Polymorphism, Restriction Fragment Length
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946800
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947628
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947148
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946611
Most Viewed Current Articles
21 Jun 2024 : Case report
97,828
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,727
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
32,839
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,613
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030